EP2405899A2 - Valsartan-formulierungen - Google Patents
Valsartan-formulierungenInfo
- Publication number
- EP2405899A2 EP2405899A2 EP10726655A EP10726655A EP2405899A2 EP 2405899 A2 EP2405899 A2 EP 2405899A2 EP 10726655 A EP10726655 A EP 10726655A EP 10726655 A EP10726655 A EP 10726655A EP 2405899 A2 EP2405899 A2 EP 2405899A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- valsartan
- microcrystalline cellulose
- pregelatinized starch
- tablet
- silicon dioxide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
Definitions
- the present invention relates to a new pharmaceutical formulation in the form of a tablet consisting of valsartan as an active agent, pregelatinized starch, microcrystalline cellulose.
- Valsartan a compound having the chemical name N-(1-oxopentyl)-N-[[2'-(1h-tetrazol-5- yl)[1 ,1 '-biphenyl]-4-yl]methyl]-L-valine, of formula I
- Valsartan belongs to the group of drugs that block receptors of angiotensin Il and thus cause a decrease of blood pressure.
- Presently valsartan tablets are marketed by Novartis as DIOVAN® in doses of 40, 80, 160 and 320 mg and it is used to treat hypertension.
- WO 9524901 A1 (CIBA-GEIGY AG) 07.03.1995, page 6 is directed to the use of valsartan for the treatment of diabetic nephropathy.
- a hard gelatine capsule comprising valsartan is disclosed.
- the described capsule dosage form above is prepared by below method. Valsartan and microcrystalline cellulose are granulated via wet granulation with solution of polyvidone and sodium lauryl sulphate in water. The granules are dried. Crospovidone and magnesium stearate are added to the dry granulate and the mixture is filled into capsules.
- the first fifth components above formulation are mixed and compacted at pressures 25 to 65 kN.
- the compacted material is further forced through a sieve.
- Granulate produced in this way is mixed with magnesium stearate and the mixture is compressed into tablets.
- WO 9749394 A2 discloses compressed solid oral dosage forms, e.g., by compaction of valsartan (optionally in salt form) optionally combined with HCTZ.
- the preferred range of cellulose is given 10 to 30%, e.g., 21%, for valsartan/HCTZ compositions and 5% valsartan alone.
- the preferred range of crospovidone is given as 10 to 20%, e.g., 13%.
- WO 0038676 A1 (NOVARTIS AG) 22.12.1999, page 24, lines 23-30 the application relates to a solid oral dosage form comprising valsartan as the active agent and microcrystalline cellulose wherein the weight ratio of valsartan to microcrystalline cellulose is from 2.5:1 to 0.3:1 , e.g., 2:1 to 1 :1 , e.g., 1.4:1.
- This application relates to a solid oral dosage form comprising valsartan as the active agent and more than 30% of microcrystalline cellulose by weight based on the total weight of the core components of said solid oral dosage form e.g., 31 to 65%, e.g., 50%.
- this application relates to a solid oral dosage form comprising valsartan as the active agent and microcrystalline cellulose wherein the weight ratio of valsartan to microcrystalline cellulose is from 2.5:1 to 0.3:1 , e.g., 2:1 to 1 :1 , e.g., 1.4:1
- the tablet material described in this application includes, apart from the valsartan active substance, optionally valsartan in combination with HCTZ, other additives, of which the most important one is suitably selected filler, which has a decisive importance for quality of the produced tablets.
- filler having a defined particle size and in defined amount.
- a preferable composition of the filler according to the invention WO 2005041941 A2 is microcrystalline cellulose having a particle size of 10 to 1000 ⁇ m, preferably 50 to 190 ⁇ m, especially preferably 90 ⁇ m, in amounts above 40 to 60% by weight, spray-dried anhydrous lactose having a particle size of 10 to 250 ⁇ m, preferably 150 to 250 ⁇ m, in amounts of 30 to 60%, compact lactose hydrate having particle size of 10 to 250 ⁇ m, in amounts 40 to 60% by weight, a polyalcohol selected from mannitol or sorbitol, which is compacted and has a particle size of 100 to 850 ⁇ m, preferably 200 to 400 ⁇ m, in amounts of 40 to 60% by weight, calcium hydrogen phosphate having particle size of 10 to 200 ⁇ m in amounts of 40 to 60% by weight, a combination of microcrystalline cellulose with lactose, preferably spray-dried anhydrous lactose, in a weight ratio of 1 :2 to 2:1 in amounts of 20 to 55%, and
- Summary of the Invention Objective of the present invention is to create a tablet containing valsartan as active ingredient, which has high powder flowability and easily divided into two or more pieces while being stable enough for transport and commercial use and that resists humidity for several days without taking up moisture or breaking apart if unblistered.
- Valsartan is a white to practically white fine powder. It is soluble in ethanol and methanol and slightly soluble in water. In state of the art valsartan is micronized to obtain better dissolution. This process causes flowability problem in manufacturing. While in the state of the art tablets are known, said tablets have several disadvantages. Normally those tablets are very porous and thus not very hard. As a consequence they cannot be broken into two or more pieces, which renders them useless for regiments wherein only one half of a tablet shall be taken at a time. Additionally these porous tablets tend to be very sensitive to humidity. As a consequence they can not be stored for some days once the blister is opened.
- the present invention relates a pharmaceutical formulation in the form of a tablet consisting of
- the tabletting mixture includes substances that improve its flow properties.
- Microcrystalline cellulose and pregelatinized starch are the most advantageous substance for the described mixture in this invention; preferably in a weight ratio of microcrystalline cellulose to pregelatinized starch is greater than 0.1 and less than 1.0. This ratio is calculated by dividing the weight of microcrystalline cellulose to the weight of pregelatinized starch. Ratio of these substances is important for avoiding fluctuations of the tablet weight, caused by inappropriate flow of the solid mixture through the hopper into the high performance tabletting machine.
- the tablet has 80 mg to 320 mg valsartan.
- the tablet contains one or more filling and/or disintegrating agents. These agents are useful to produce tablets of a certain size and to support flowability step.
- the filling and/or disintegrating agents are microcrystalline cellulose and pregelatinized starch.
- the tablet also contains one or more lubricant or glidant. Lubricants and glidants are well known in the state of the art. Among them, the lubricant(s) are selected from the group of stearate, preferably magnesium stearate.
- the glidant(s) are selected from the group of silicon dioxide, preferably colloidal silicon dioxide.
- invention in the form of a tablet consisting of 20 to 34% of valsartan
- magnesium stearate 0.5 to 4.5% of magnesium stearate.
- the tablets that described in examples are produced by direct compression techniques.
- valsartan, microcrystalline cellulose, pregelatinized starch are mixed. Colloidal silicon dioxide are added to this powder and mixed. Then magnesium stearate are added to this powder and mixed. Finally, mixture is compressed by tablet compression machine.
- the present invention relates to tablet comprising valsartan as the active agent, microcrystalline cellulose and pregelatinized starch wherein the weight ratio of microcrystalline cellulose to pregelatinized starch is greater than 0.1 and less than 1.0.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Zoology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TR200901901 | 2009-03-11 | ||
PCT/TR2010/000046 WO2010104485A2 (en) | 2009-03-11 | 2010-03-10 | Valsartan formulations |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2405899A2 true EP2405899A2 (de) | 2012-01-18 |
Family
ID=41226269
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP10726655A Ceased EP2405899A2 (de) | 2009-03-11 | 2010-03-10 | Valsartan-formulierungen |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP2405899A2 (de) |
WO (1) | WO2010104485A2 (de) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013191668A1 (en) * | 2012-06-22 | 2013-12-27 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Compositions preventing hypertension comprising soluplus |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1994926A1 (de) * | 2007-05-24 | 2008-11-26 | Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi | Valsartanformulierungen |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SK117996A3 (en) | 1994-03-17 | 1997-03-05 | Ciba Geigy Ag | Pharmaceutical composition for treatment of diabetic nephropathy |
GB9613470D0 (en) | 1996-06-27 | 1996-08-28 | Ciba Geigy Ag | Small solid oral dosage form |
CZ297795B6 (cs) | 1998-12-23 | 2007-03-28 | Novartis Ag | Tablety obsahující valsartan |
EP1680095A2 (de) | 2003-11-03 | 2006-07-19 | Zentiva, a.s. | Valsartan enthaltende formulierung |
EA015108B1 (ru) * | 2004-12-24 | 2011-06-30 | КРКА, д.д., НОВО МЕСТО | Способ получения твердой фармацевтической композиции, содержащей валсартан |
US20090215756A1 (en) * | 2005-05-18 | 2009-08-27 | Combino Pharm, S.L. | Formulations containing losartan and/or its salts |
GT200600371A (es) * | 2005-08-17 | 2007-03-21 | Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas | |
US20090304755A1 (en) * | 2005-10-27 | 2009-12-10 | Raghu Rami Reddy Kasu | Pharmaceutical formulation of losartan |
WO2007049291A1 (en) * | 2005-10-27 | 2007-05-03 | Lupin Limited | Novel solid dosage forms of valsartan and rochlorothiazide |
US20080227836A1 (en) * | 2005-10-31 | 2008-09-18 | Lupin Ltd | Stable Solid Oral Dosage Forms of Valsartan |
-
2010
- 2010-03-10 EP EP10726655A patent/EP2405899A2/de not_active Ceased
- 2010-03-10 WO PCT/TR2010/000046 patent/WO2010104485A2/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1994926A1 (de) * | 2007-05-24 | 2008-11-26 | Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi | Valsartanformulierungen |
Non-Patent Citations (1)
Title |
---|
See also references of WO2010104485A2 * |
Also Published As
Publication number | Publication date |
---|---|
WO2010104485A2 (en) | 2010-09-16 |
WO2010104485A3 (en) | 2010-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2955495C (en) | High dosage strength tablets of rucaparib | |
EP1994926B9 (de) | Valsartanformulierungen | |
JP6895779B2 (ja) | アジルサルタン含有固形医薬組成物 | |
JP2014024874A (ja) | 圧縮製剤 | |
KR101479824B1 (ko) | 용출 안정성 제제 | |
AU2013365715B2 (en) | A pharmaceutical composition containing candesartan cilexetil and amlodipine | |
JP2020114834A (ja) | セリチニブ製剤 | |
EP2067470A1 (de) | Pharmazeutische Zusammensetzungen mit Valsartan und Herstellungsverfahren dafür | |
JP2014037356A (ja) | カンデサルタンシレキセチル経口製剤 | |
CA2609026A1 (en) | Formulations containing losartan and/or its salts | |
EP2405899A2 (de) | Valsartan-formulierungen | |
JP2011136908A (ja) | アンギオテンシンii受容体拮抗剤を含む固形製剤および固形製剤におけるアンギオテンシンii受容体拮抗剤の保存安定性向上方法 | |
EP2379061B1 (de) | Vorkompaktierte schnell zerfallende Formulierungen von Verbindungen mit geringer oraler Bioverfügbarkeit | |
CN102614188A (zh) | 含有缬沙坦、左旋氨氯地平和氢氯噻嗪的胶囊剂及其制法 | |
CZ2016785A3 (cs) | Farmaceutická kompozice obsahující nilotinib a způsob její přípravy | |
SK50472005A3 (sk) | Tableta s obsahom valsartanu vyrobená priamym tabletovaním | |
EP2471520B1 (de) | Pharmazeutische Levetiracetam-Zusammensetzungen | |
JP2015063570A (ja) | 口腔内崩壊錠 | |
RU2007147953A (ru) | Фармацевтические рецептуры микронизированного (4-хлорфенил)[4-(4-пиридилметил)-фталазин-1-ила] и его солей с немедленным высвобождением и высоким содержанием лекарственного средства | |
BG108034A (bg) | Фармацевтичен състав, съдържащ циталопрам | |
CZ297417B6 (cs) | Lécivý prípravek obsahující valsartan | |
JP2005015363A (ja) | 小型化クラリスロマイシン錠剤 | |
CZ294505B6 (cs) | Tableta s obsahem valsartanu vyrobená přímým tabletováním | |
CA2785920A1 (en) | Solid oral dosage form containing olmesartan medoxomil | |
JP2009542806A (ja) | 感湿性薬物及び第2薬物の組合せを含んで成る安定製剤及びその製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20111003 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20120820 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R003 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
18R | Application refused |
Effective date: 20131009 |